CLINICAL_TRIALS
trial_result
· 2018-10-26
Clinical Trial Update: Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg [Phase 4]
Summary
Phase 4 trial comparing steady-state bioavailability of Lozanoc 50 mg with Sporanox 100 mg in prophylaxis patients completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mayne Pharma International Pty Ltd | Conditions: Neutropenia | Phase 4 | Status: COMPLETED